OTHER FUNCTIONS NANOSORT"PHASE I, TOPIC 309, FLOWNOSTICS: PORTABLE MULTIPLEX ANA

其他功能 Nanosort”第一阶段，主题 309，FLOWNOSTICS：便携式 MULTIPLEX ANA

• 批准号: 8566222
• 金额: $ 19.97万
• 依托单位: NANOCELLECT BIOMEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-28 至 2013-06-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8566222
• 关键词: Biological Assay; Blood specimen; Code; Color; Complex; Coulter counter; Detection; Devices; Discrimination; Disease; Early Diagnosis; Hematopoietic Neoplasms; Improve Access; Lasers; Malignant Neoplasms; Microfluidic Microchips; Microscopic; Microspheres; Mission; Monitor; Optics; Phase; Proteins; Public Health; Quantum Dots; Reporting; Sampling; Screening for cancer; Solutions; Staging; System; Technology; Time; United States National Institutes of Health; Urine; base; cost; detector; electric impedance; improved; micro-total analysis system; novel; point-of-care diagnostics

Cancer is a complex and diverse disease whose treatment can be improved by more sophisticated early detection and monitoring. NanoSort, Inc. proposes to build a lab-on-a-chip microfluidic device platform that can detect and quantify up to 32 multiplexed analytes for the detection and monitoring of cancer from blood or urine samples. This novel "FlowNostics" device will utilize 32 kinds of microscopic beads, coded by their size and color, that will be detected by a combination of impedence and a single optical detector to detect emission from single laser excitation. NanoSort's FlowNostics platform will reduce the expense and complexity of flow cytometric-based multiplex assays to increase access and point-of-care diagnostics. NanoSort's FlowNostics technology will improve public health and help to fulfill the mission of the NIH and NCI by improving access to sophisticated analytics at a fraction of the cost and complexity of current devices. NanoSort's aim is to make routine blood samples taken during check-ups capable of reporting the presence of cancer, which will aid in the early detection of cancer and allow treatments before cancers have reached an advanced stage.

癌症是一种复杂而多样的疾病，通过更复杂的早期检测和监测可以改善治疗。NanoSort公司提议建立一个芯片实验室微流控装置平台，该平台可以检测和量化多达32种多路分析物，用于检测和监测血液或尿液样本中的癌症。这种新颖的“流体探测”装置将利用32种微珠，根据它们的大小和颜色进行编码，这些微珠将通过阻抗和单个光学探测器的组合来检测单个激光激发的发射。NanoSort的FlowNostics平台将降低基于流式细胞术的多重检测的费用和复杂性，从而增加可及性和即时诊断。